Automated Cell Processing
Automated Cell Processing
The goal of cell processing is to isolate and extract the maximum amount of valuable cells without contamination or damage. Whether we’re processing an infant’s cord blood or an adult’s whole blood, preserving the highest quality and quantity of cells ensures they will be ready for future clinical use without any risk of complication.
Cell Processing Method
Cell processing is such an important part of cord blood and immune cell banking, yet not many customers truly understand how the process works. There are two major methods:
Manual Processing – This is generally the most common cell processing method used in the majority of cell banks. Many cell banks advertise a unique and proprietary processing method in which trained lab technicians process cells by hand.
Automated Cell Processing – Cord blood or whole blood is automatically processed in a highly sophisticated, FDA approved, and functionally closed device such as the AXP or the MCASS platform utilized by HealthBanks.
See the chart below, comparing the different cell processing methods to get a better understanding of the differences.
Pros and Cons of Manual Cell Processing vs Automated Cell Processing
| Manual Cell Processing | Automated Cell Processing | |
| Advantages |
Less Expensive. |
|
| Disadvantages |
|
More Expensive as the cell bank needs to purchase a highly sophisticated and FDA approved device. |
Also review this compare cell banks to see who is using automated cell processing vs manual cell processing
HealthBanks AXP Automated Cell Processing Platform for Cord Blood
HealthBanks innovative AXP® II System defines the highest processing standard for isolating and retrieving stem cells from umbilical cord blood.
The AXP® II System:
- Is a fully-automated, fully-closed, and sterile system that volume reduces cord blood to prevent human error and contamination that can occur in manual processing systems.
- Possess a self-powered and advanced microprocessor and contains flow control optical sensors that help achieve the most precise cell separation and highest cell recovery- an important step prior to cell storage.
- Delivers high yields, consistently producing the highest MNC recoveries in the industry.¹ Published studies show that the AXP™ allows HealthBanks to achieve 97.9% mononuclear cell (MNC) recoveries compared to other processing systems.
Source: ᴵNew York Blood Center
HealthBanks MCASS Automated Cell Processing Platform for Immune Cell Banking
HealthBanks’ MCASS platform provides a stream-lined solution for cell processing, selection, washing, and cryopreservation for immune cells. It allows simultaneous isolation of different cell components from blood within a closed system, ensuring safe and quality assurance for the future. This system is not available for use at any other US-based cell bank. Without utilizing proprietary and automated technology, immune cells can only be extracted using a Ficoll manual method, leading to a higher risk of contamination and lower cell quality.
Comparison of MCASS vs Ficoll Manual Processing
Subscribe to Our Newsletter & Special Promotions
Disclaimer: The use of cord blood and immune cells is determined by the treating physician and manufacturer of the final products and is influenced by many factors, including the patient's medical condition, the characteristics of the sample, and whether the immune cells should be further modified or expanded. Cord blood has established uses in transplant medicine; however, its use in regenerative medicine is still being researched. There is no guarantee that potential medical applications being studied in the laboratory or clinical trials will become available. Cord tissue use is still in early research stages, and there is no guarantee that treatments using cord tissue will be available in the future. Cord tissue is stored whole. Additional processing prior to use will be required to extract and prepare any of the multiple cell types from cryopreserved cord tissue. Immune cells has established uses in certain blood cancer treatment; however, its use in solid cancer is still being researched. There is no guarantee that treatments being studied in the laboratory, clinical trials, or other experimental treatments will be available in the future.
HealthBanks cryopreserves immune cells that have been collected from an individual for potential future cellular therapy use. HealthBanks does not provide medical advice, treatment or care. The use of cryopreserved cells for future immunotherapies is not guaranteed. Much is yet unknown about the future of immunotherapy and the immune cells that have been cryopreserved. The use of cryopreserved cells by commercial manufacturers for CAR-T therapy production is not currently approved by the FDA. There is active research ongoing, however, there is no guarantee that your cryopreserved cells will have a future therapeutic use. Only your health care professional can help you evaluate whether your cells might be used and if so, how they might be used. HealthBanks and its shareholders, directors, officers, agents, employees, affiliates, network of providers and provider facilities, will not be liable to you or any other party for claims relating to sample collection or if your cells cannot be used, or if any harm, injury, damage or loss results from the use of your cells. For more information, please refer to HealthBanks Service Agreement.